Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial

MLA

Su H, et al. “Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial.” International Journal of Women’s Health, vol. ume 17, Feb. 2025, pp. 325–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1dce20a64407dbc8abd4d73a485a9&authtype=sso&custid=ns315887.

APA

Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, & Feng F. (2025). Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial. International Journal of Women’s Health, ume 17, 325–333.

Chicago

Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, and Feng F. 2025. “Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial.” International Journal of Women’s Health ume 17 (February): 325–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.1dce20a64407dbc8abd4d73a485a9&authtype=sso&custid=ns315887.